Adipotide (FTPP)
Typical Dosing Protocols (Research/Compounded Use Only) – Adipotide (FTPP)
Common protocol: 250–500 mcg subcutaneously once daily (approximately 0.01 mg/kg body weight). Most users start at 250 mcg daily for the first 1–2 weeks, then titrate up to 500 mcg.
Other reported ranges:
Standard: 250–500 mcg daily
Higher: 500–1,000 mcg daily (less common)
Cycle length: Strictly limited to 2–4 weeks maximum (often 28 days), followed by at least an equal or longer break (4+ weeks).
Reconstitution example (for a typical 5–10 mg vial): Add 2–3 mL bacteriostatic water.
250 mcg = 0.05–0.1 mL (5–10 units on U-100 insulin syringe)
500 mcg = 0.1–0.2 mL (10–20 units)
Administration: Subcutaneous injection (abdomen or thigh), usually in the morning on an empty stomach.
Dosing is highly individualized based on goals (targeted fat loss) and response—consult a qualified healthcare provider experienced with peptides for personalized guidance. This is for informational purposes only.
Key Potential Benefits of Adipotide (FTPP)
Targeted Apoptosis of White Adipose Tissue Vasculature
Selectively binds to prohibitin and annexin A2 receptors on endothelial cells of blood vessels supplying white fat, disrupting their blood supply.
Induces programmed cell death (apoptosis) specifically in the vasculature feeding white adipose tissue while largely sparing other tissues.
Leads to progressive reduction in fat cell size and number through vascular starvation, rather than simply shrinking existing fat cells.
Significant Reduction in Body Fat and Weight Loss
Promotes rapid and substantial decreases in overall body fat mass, particularly visceral and abdominal (central) fat deposits.
In obese primate models, associated with 7–15% body weight reduction and notable decreases in BMI and abdominal circumference over 4 weeks.
Supports more permanent fat cell elimination compared to traditional methods that primarily reduce fat cell volume.
Improved Metabolic Health and Insulin Sensitivity
Enhances glucose tolerance and insulin sensitivity by reducing harmful visceral fat that contributes to metabolic dysfunction.
Lowers markers of insulin resistance independently of overall weight loss in certain research contexts.
Contributes to better lipid profiles and metabolic flexibility through targeted adipose tissue remodeling.
Appetite Regulation and Reduced Food Intake
Associated with decreased caloric intake in obese models without signs of nausea, illness, or aversion to food.
Helps shift energy balance by reducing fat mass, which indirectly influences hunger signaling pathways.
Supports sustainable changes in body composition during fat-loss phases.
Preservation of Lean Muscle Mass
Facilitates fat-specific loss while helping maintain lean tissue and muscle mass during significant weight reduction.
Avoids broad catabolic effects seen with some non-selective weight-loss approaches.
Contributes to improved body composition by prioritizing adipose tissue reduction over muscle.
Broader Support for Metabolic Resilience
May aid in counteracting obesity-related complications by reducing ectopic fat accumulation and improving overall energy homeostasis.
Supports physiological adaptations that favor long-term metabolic health and reduced inflammation linked to excess white fat.
Provides a novel mechanism for addressing stubborn fat resistant to diet and exercise alone.
These benefits are primarily observed in preclinical rodent and primate studies, with limited human data available. Adipotide (also known as FTPP) works through a unique vascular targeting mechanism rather than hormonal or appetite-suppressant pathways.
){kind=link}